Biosimilar Reference Antibody-GS40400 新品

货号：GS40400

Loncastuximab is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody targeting CD19, a B‑lineage surface antigen, conjugated to a potent pyrrolobenzodiazepine (PBD) dimer toxin via a cleavable linker. Upon binding to CD19 on malignant B cells, the ADC is internalized, and the linker is cleaved to release the cytotoxic PBD payload. The PBD dimer cross‑links DNA, causing irreversible DNA damage and leading to cell cycle arrest and apoptosis. It is approved for the treatment of relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more prior lines of systemic therapy.